Physician profile
Amy Schepens
NPI 1255446027
$514.72
in general payments reported to CMS, 2019-2025
14 companies · $40.80 in 2025
The $40.80 reported for 2025 was less than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $172 · 2020: $113 · 2021: $43.38 · 2022: $31.03 · 2023: $34.41 · 2024: $80.06 · 2025: $40.80.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $155.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $155.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $82.77 | 2019-2020 | |
| Sanofi Pasteur INC. | $67.19 | 2019 | |
| Glaxosmithkline, LLC. | $67.12 | 2019-2023 | Pediarix, Bexsero, Rotarix |
| Merck Sharp & Dohme LLC | $55.98 | 2022-2024 | Gardasil 9, Vaqta, Vaxelis |
| Adlon Therapeutics L.P. | $38.33 | 2020 | |
| Ironshore Pharmaceuticals INC. | $36.46 | 2024 | |
| Boston Scientific Corporation | $28.72 | 2021 | |
| Tris Pharma INC | $27.20 | 2019-2021 | |
| Supernus Pharmaceuticals, INC. | $22.45 | 2024 | Qelbree |
| Alnylam Pharmaceuticals INC. | $21.95 | 2025 | Oxlumo |
| Cipher Pharmaceuticals US LLC | $18.85 | 2025 | Spinosad, Natroba |
| Neos Therapeutics, Lp | $18.36 | 2019 | |
| Shire North American Group INC | $16.08 | 2019 | |
| Pfizer INC. | $13.26 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Schepens listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.